Skip to content
zameds

Dovipsa

Active ingredient not listed in the SAHPRA register

Glaxosmithkline South Africa (Pty) Limited

Registration

Applicant
Glaxosmithkline South Africa (Pty) Limited
Certificate holder
Glaxosmithkline South Africa (Pty) Limited
Registrations
1

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Dovipsa50 mg. 300 mgFilm-coated tablet54040754/20.2.8/0407Approved 1 December 2020RegisteredNot determinedPIPIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

No structure available

The SAHPRA register lists no active ingredient for this product, so there is no compound to show.

SAHPRA documents

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles